litlas
Log inCreate account

Javier de Castro

Active 2003–2025

Also published as
Javier De Castro
61
Papers
21,982
Citations
38
h-index
56
i10-index

Citations

Citations per year for Javier de Castro1971: 3 citations1976: 1 citations1993: 1 citations1995: 1 citations2001: 2 citations2003: 1 citations2004: 7 citations2005: 32 citations2006: 22 citations2007: 31 citations2008: 24 citations2009: 21 citations2010: 23 citations2011: 32 citations2012: 61 citations2013: 132 citations2014: 122 citations2015: 161 citations2016: 140 citations2017: 121 citations2018: 223 citations2019: 901 citations2020: 1,085 citations2021: 1,115 citations2022: 906 citations2023: 735 citations2024: 1,141 citations2025: 555 citations2026: 10 citations1972–1975: no citations, so these years are not shown1977–1992: no citations, so these years are not shown1994: no citations, so this year is not shown1996–2000: no citations, so these years are not shown2002: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,377 citing papers, 20.9% of this breakdownChina: 2,078 citing papers, 18.3% of this breakdownItaly: 632 citing papers, 5.6% of this breakdownJapan: 567 citing papers, 5% of this breakdownUnited Kingdom: 546 citing papers, 4.8% of this breakdownSpain: 461 citing papers, 4.1% of this breakdownFrance: 461 citing papers, 4.1% of this breakdownGermany: 429 citing papers, 3.8% of this breakdownCanada: 318 citing papers, 2.8% of this breakdownSouth Korea: 296 citing papers, 2.6% of this breakdownNetherlands: 296 citing papers, 2.6% of this breakdownAustralia: 252 citing papers, 2.2% of this breakdown
0%20.9%Other 23.2%

Institutions

Fields

  • Medicine77.8%
  • Biochemistry, Genetics and Molecular Biology15.9%
  • Immunology and Microbiology2.6%
  • Engineering0.5%
  • Neuroscience0.5%
  • Pharmacology, Toxicology and Pharmaceutics0.5%
  • Other2.2%

Topics

  • Lung Cancer Treatments and Mutations12.9%
  • Cancer Immunotherapy and Biomarkers12.4%
  • Lung Cancer Research Studies7.6%
  • Lung Cancer Diagnosis and Treatment7.3%
  • Cancer Genomics and Diagnostics3.1%
  • Immunotherapy and Immune Responses2.4%
  • Other54.3%

Coauthors

All papers

Open in search
  1. Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

    Authors: Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takashi Yokoi, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Catherine Wadsworth, Giovanni Melillo, Haiyi Jiang, Yifan Huang, Phillip A. Dennis, Mustafa Özgüroğlu - New England Journal of Medicine 2017 cited by 4,539

  2. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

    Authors: Scott Antonia, Augusto Villegas, Davey B. Daniel, David Vicente, Shuji Murakami, Rina Hui, Takayasu Kurata, Alberto Chiappori, Ki Hyeong Lee, Maike de Wit, Byoung Chul Cho, Maryam Bourhaba, Xavier Quantin, Takaaki Tokito, Tarek Mekhail, David Planchard, Young‐Chul Kim, Christos S. Karapetis, Sandrine Hiret, Gyula Ostoros, Kaoru Kubota, Jhanelle E. Gray, Luis Paz‐Ares, Javier de Castro, Corinne Faivre‐Finn, Martin Reck, Johan Vansteenkiste, David R. Spigel, Catherine Wadsworth, Giovanni Melillo, Maria Taboada, Phillip A. Dennis, Mustafa Özgüroğlu - New England Journal of Medicine 2018 cited by 2,800

  3. Updated Overall Survival and PD-L1 Subgroup Analysis of Patients With Extensive-Stage Small-Cell Lung Cancer Treated With Atezolizumab, Carboplatin, and Etoposide (IMpower133)

    Authors: Stephen V. Liu, Martin Reck, Aaron S. Mansfield, Tony Mok, Arnaud Scherpereel, Niels Reinmuth, Marina Chiara Garassino, Javier de Castro, Raffaele Califano, Makoto Nishio, Francesco Orlandi, Jorge Alatorre-Alexander, Ticiana Leal, Ying Cheng, Jong Seok Lee, Sivuonthanh Lam, Mark L. McCleland, Yu Deng, See Phan, Leora Horn - Journal of Clinical Oncology 2021 cited by 824

  4. PI3K/Akt signalling pathway and cancer

    Authors: Juan Ángel Fresno Vara, E. Casado, Javier de Castro, Paloma Cejas, Cristóbal Belda-Iniesta, Manuel González-Barón - Cancer Treatment Reviews 2003 cited by 2,490

  5. Perioperative Nivolumab and Chemotherapy in Stage III Non–Small-Cell Lung Cancer

    Authors: Mariano Provencio, Ernest Nadal, J.L. González-Larriba, Alex Martínez‐Martí, Reyes Bernabé, Joaquim Bosch‐Barrera, Joaquín Casal‐Rubio, Virginia Calvo, Amelia Insa, Santiago Ponce, Noemı́ Reguart, Javier de Castro, Joaquín Mosquera, Manuel Cobo, Andrés Aguilar, Guillermo López-Vivanco, Carlos Camps, Rafael López Castro, Teresa Morán, I. Barneto, Delvys Rodríguez‐Abreu, Roberto Serna‐Blasco, Raquel Benítez, Carlos Aguado, Ramón Palmero, Florentino Hernándo, Javier Martín-López, Alberto Cruz‐Bermúdez, Bartomeu Massutí, Atocha Romero - New England Journal of Medicine 2023 cited by 450

  6. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

    Authors: Rafael Rosell, Enric Carcereny, Radj Gervais, A. Vergnenègre, Bartomeu Massutí, Enriqueta Felip, Ramón Palmero, Ramón García-Gómez, Cinta Pallarés, José Miguel Sánchez, Rut Porta, Manuel Cobo, Pilar Garrido, Flavia Longo, Teresa Morán, Amelia Insa, Filippo de Marinis, R. Corre, Isabel Bover, Alfonso Illiano, Éric Dansin, Javier de Castro, Michèle Milella, Noemı́ Reguart, Giuseppe Altavilla, Ulpiano Jiménez, Mariano Provencio, Miguel Ángel Moreno, Josefa Terrasa, José Muñoz-Langa, Javier Valdivia, Dolores Isla, Manuel Dómine, Olivier Molinier, Julien Mazières, Nathalie Baize, Rosario García‐Campelo, G. Robinet, Delvys Rodríguez‐Abreu, Guillermo López-Vivanco, Vittorio Gebbia, Lioba Ferrera-Delgado, P. Bombaron, Reyes Bernabé, Alessandra Bearz, Á. Artal, Enrico Cortesi, Christian Rolfo, María Sanchez-Ronco, Ana Drozdowskyj, Cristina Queralt, Itziar de Aguirre, José Luis Ramírez, José Javier Sánchez, Miguel Ángel Molina‐Vila, Miquel Tarón, Luis Paz‐Ares - The Lancet Oncology 2012 cited by 5,530

  7. Neoadjuvant chemotherapy and nivolumab in resectable non-small-cell lung cancer (NADIM): an open-label, multicentre, single-arm, phase 2 trial

    Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, María Rosario García-Campelo, Joaquín Casal‐Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Marta Casarrubios, Clara Salas, Edwin R. Parra, Ignacio I. Wistuba, Virginia Calvo, Raquel Laza‐Briviesca, Atocha Romero, Bartomeu Massutí, Alberto Cruz‐Bermúdez - The Lancet Oncology 2020 cited by 828

  8. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

    Authors: Hossein Borghaei, Scott Gettinger, Everett E. Vokes, Laura Q.M. Chow, Marco Angelo Burgio, Javier de Castro, Adam Płużański, Óscar Arrieta, Osvaldo Arén Frontera, Rita Chiari, Charles Butts, Joanna Wójcik-Tomaszewska, Bruno Coudert, Marina Chiara Garassino, Neal Ready, Enriqueta Felip, M. Alonso Garcìa, David Waterhouse, Manuel Dómine, Fabrice Barlési, Scott Antonia, M Wohlleber, David E. Gerber, Grzegorz Czyżewicz, David R. Spigel, Lucio Crinò, Wilfried Eberhardt, Ang Li, S. Marimuthu, Julie R. Brahmer - Journal of Clinical Oncology 2021 cited by 661

  9. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non–Small-Cell Lung Cancer (NADIM phase II trial)

    Authors: Mariano Provencio, Roberto Serna‐Blasco, Ernest Nadal, Amelia Insa, M.R. García-Campelo, J. Casal Rubio, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Eva Pereira, Ana Royuela, Virginia Calvo, Javier Martín-López, Francisco Garcia‐García, Marta Casarrubios, Fernando Franco, Estela Sánchez‐Herrero, Bartomeu Massutí, Alberto Cruz‐Bermúdez, Atocha Romero - Journal of Clinical Oncology 2022 cited by 335

  10. Trastuzumab Emtansine (T-DM1) in Patients with Previously Treated HER2-Overexpressing Metastatic Non–Small Cell Lung Cancer: Efficacy, Safety, and Biomarkers

    Authors: Solange Peters, Rolf A. Stahel, Lukas Bubendorf, Philip Bonomi, Augusto Villegas, Dariusz M. Kowalski, Christina S. Baik, Dolores Isla, Javier de Castro, Pilar Garrido, Achim Rittmeyer, Marcello Tiseo, Christoph Meyenberg, Sanne de Haas, Lisa H. Lam, Michael W. Lu, Thomas E. Stinchcombe - Clinical Cancer Research 2018 cited by 230

  11. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non–Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

    Authors: Ernest Nadal, Delvys Rodríguez‐Abreu, Marta Simó, Bartomeu Massutí, Óscar Juan, G. Huidobro, Rafael López Castro, Javier de Castro, Anna Estival, Joaquín Mosquera, Ivana Sullivan, Enriqueta Felip, Ana Blasco, M. Guirado, Eva Pereira, Noelia Vilariño, Valentín Navarro, Jordi Bruna - Journal of Clinical Oncology 2023 cited by 106

  12. Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis

    Authors: Scott Antonia, Hossein Borghaei, Suresh S. Ramalingam, Leora Horn, Javier de Castro, Adam Płużański, Marco Angelo Burgio, Marina Chiara Garassino, Laura Q.M. Chow, Scott Gettinger, Lucio Crinò, David Planchard, Charles Butts, Alexander Drilon, Joanna Wójcik-Tomaszewska, Gregory A. Otterson, Shruti Agrawal, Ang Li, John R. Penrod, Julie R. Brahmer - The Lancet Oncology 2019 cited by 365

  13. A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial

    Authors: Ross A. Soo, Ji‐Youn Han, Urania Dafni, Byoung Chul Cho, Chong Ming Yeo, Ernest Nadal, Enric Carcereny, J. de Castro, María Ángeles Sala, Reyes Bernabé, Linda Coate, M. Provencio Pulla, Rosario García Campelo, Sinéad Cuffe, Sayed M.S. Hashemi, Martin Früh, Bartomeu Massutí, José García-Sánchez, Manuel Dómine, Margarita Majem, J.M. Sánchez-Torres, Christian Britschgi, Miklos Pless, Georgia Dimopoulou, Heidi Roschitzki‐Voser, Barbara Ruepp, Rafael Rosell, Rolf A. Stahel, Solange Peters, Rolf A. Stahel, Solange Peters, Ross A. Soo, Ji‐Youn Han, Martin Früh, Mariano Provencio, Linda Coate, Urania Dafni, Anita Hiltbrunner, Barbara Ruepp, Heidi Roschitzki‐Voser, Anita Hiltbrunner, Adriana Gasca-Ruchti, Nino Giacomelli, Rosita Kammler, Nesa Marti, Lionel Nobs, Mariana Pardo-Contreras, Rita Pfister, Anne‐Christine Piguet, Sabrina Ribeli-Hofmann, Virginia Rodriguez Martinez, Heidi Roschitzki‐Voser, Susanne Roux, Barbara Ruepp, Magdalena Sánchez-Hohl, Mirjam Schneider, Robin Schweri, Sandra Troesch, Isabel Zigomo, Urania Dafni, Zoi Tsourti, Panagiota Zygoura, Marie Kassapian, Katerina Vervita, Georgia Dimopoulou, Charitini Andriakopoulou, Maria Fernandez, Eva Pereira, Carolina Simona, Lisa Tucker, Jillian Burnes, Aisling Barrett, Meghan McGrillen, Catherine Berset, Christine Biaggi, M. Reist, Priska Rentsch, Linda Coate, Sinéad Cuffe, Sayed M.S. Hashemi, Ernest Nadal, Enric Carcereny, Javier de Castro, María Ángeles Sala, Bernabé Reyes, Mariano Provencio Pulla, Rosario García Campelo, Bartomeu Massutí, José López García, Manuel Dómine, Margarita Majem, José Miguel Sánchez, Martin Früh, Christian Britschgi, Miklos Pless, Solange Peters, Ross A. Soo, Chong Ming Yeo, Ji‐Youn Han, Byoung Chul Cho - Annals of Oncology 2021 cited by 116

  14. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Authors: Marta Casarrubios, Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García-Campelo, Martín Lázaro-Quintela, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé, Núria Viñolas, Isidoro Barneto Aranda, Bartomeu Massutí, Belén Sierra‐Rodero, Cristina Martínez-Toledo, Ismael Fernández‐Miranda, Roberto Serna‐Blasco, Atocha Romero, Virginia Calvo, Alberto Cruz‐Bermúdez - Journal for ImmunoTherapy of Cancer 2022 cited by 62

  15. Priorities in Cardio-Oncology Basic and Translational Science

    Authors: Fadi N. Salloum, Carlo G. Tocchetti, Pietro Ameri, Hossein Ardehali, Aarti Asnani, Rudolf A. de Boer, Paul W. Burridge, José Ángel Cabrera, Javier de Castro, Raúl Córdoba, Ambra Costa, Susan Dent, Daniel Engelbertsen, María Fernández‐Velasco, Mike Fradley, José J. Fuster, Carlos Galán‐Arriola, Inés García‐Lunar, Alessandra Ghigo, Anna González‐Neira, Emilio Hirsch, Borja Ibáñez, Richard N. Kitsis, Suma Konety, Alexander R. Lyon, Pilar Martı́n, Adolfo G Mauro, Manuel M. Mazo Vega, Wouter C. Meijers, Tomas G. Neilan, Tienush Rassaf, Melanie Ricke‐Hoch, Pilar Sepúlveda, Paaladinesh Thavendiranathan, Peter van der Meer, Valentı́n Fuster, Bonnie Ky, Teresa López‐Fernández - JACC CardioOncology 2023 cited by 43

  16. Perioperative chemotherapy and nivolumab in non-small-cell lung cancer (NADIM): 5-year clinical outcomes from a multicentre, single-arm, phase 2 trial

    Authors: Mariano Provencio, Ernest Nadal, Amelia Insa, Rosario García Campelo, J. Casal, Manuel Dómine, Bartomeu Massutí, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, David Gómez de Antonio, Iván Macı́a, Santiago J. A. Figueroa, Luís Fernández Vago, Virginia Calvo, Ramón Palmero, Belén Sierra‐Rodero, Cristina Martínez-Toledo, Marta Molina-Alejandre, Roberto Serna‐Blasco, Atocha Romero, Alberto Cruz‐Bermúdez - The Lancet Oncology 2024 cited by 69

  17. Assessment of the Feasibility and Safety of Durvalumab for Treatment of Solid Tumors in Patients With HIV-1 Infection

    Authors: Maria Gonzalez-Cao, Teresa Morán, Judith Dalmau, Javier Garcia-Corbacho, Jillian W. P. Bracht, Reyes Bernabe, Oscar Juan, Javier de Castro, Remei Blanco, Ana Drozdowskyj, Jordi Argilaguet, Andreas Meyerhans, Julia Blanco, Julia G. Prado, Jorge Carrillo, Bonaventura Clotet, Bartomeu Massuti, Mariano Provencio, Miguel A. Molina-Vila, Clara Mayo de las Casa, Monica Garzon, Peng Cao, Chung-Ying Huang, Javier Martinez-Picado, Rafael Rosell - JAMA Oncology 2020 cited by 106

  18. Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

    Authors: Raquel Laza‐Briviesca, Alberto Cruz‐Bermúdez, Ernest Nadal, Amelia Insa, Rosario García-Campelo, G. Huidobro, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massutí, Marta Casarrubios, Belén Sierra‐Rodero, Carlos Tarín, Aránzazu García‐Grande, Cara Haymaker, Ignacio I. Wistuba, Atocha Romero, Fernando Franco, Mariano Provencio - Clinical and Translational Medicine 2021 cited by 56

  19. New update to the guidelines on testing predictive biomarkers in non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology

    Authors: Dolores Isla, María D. Lozano, Luis Paz‐Ares, Clara Salas, Javier de Castro, Esther Conde, Enriqueta Felip, Javier Gómez‐Román, Pilar Garrido, Ana B. Enguita - Clinical & Translational Oncology 2022 cited by 46

  20. Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

    Authors: Marta Casarrubios, Alberto Cruz‐Bermúdez, Ernest Nadal, Amelia Insa, María del Rosario García Campelo, Martín Lázaro-Quintela, Manuel Dómine, Margarita Majem, Delvys Rodríguez‐Abreu, Alex Martínez‐Martí, Javier de Castro, Manuel Cobo, Guillermo López-Vivanco, E. del Barco, Reyes Bernabé Caro, Núria Viñolas, Isidoro Barneto Aranda, Santiago Viteri, Bartomeu Massutí, Miguel Barquín, Raquel Laza‐Briviesca, Belén Sierra‐Rodero, Edwin R. Parra, Beatriz Sánchez‐Espiridión, Pedro Rocha, Humam Kadara, Ignacio I. Wistuba, Atocha Romero, Virginia Calvo, Mariano Provencio - Clinical Cancer Research 2021 cited by 67

  21. Evaluation of the clinical use of MGMT methylation in extracellular vesicle-based liquid biopsy as a tool for glioblastoma patient management

    Authors: Rocío Rosas-Alonso, Julian Colmenarejo-Fernández, Olga Pernía, Miranda Burdiel, Carlos Rodríguez‐Antolín, Itsaso Losantos-García, Tania Rubio, Rocío Moreno-Velasco, Isabel Esteban‐Rodríguez, Virginia Martínez-Marín, Paloma Yubero, Nicolás Costa‐Fraga, Ángel Díaz‐Lagares, Rafael López‐López, Eva Díaz-Martín, Juan Francisco García, Catalina Vivancos Sánchez, Maria L. Gandía-González, Gema Moreno‐Bueno, Javier de Castro, Inmaculada Ibañez de Cáceres - Scientific Reports 2024 cited by 23

  22. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial

    Authors: Piero Ferollà, Maria Pia Brizzi, Tim Meyer, Wasat Mansoor, Julien Mazières, Christine Do Cao, H. Léna, Alfredo Berruti, Vincenzo Damiano, Wieneke A. Buikhuisen, Henning Grønbæk, Catherine Lombard‐Bohas, Christian Grohé, Vincenzo Minotti, Marcello Tiseo, Javier De Castro, Nicholas Reed, Gabriella Gislimberti, Neha Singh, Miona Stankovic, Kjell Öberg, Éric Baudin - The Lancet Oncology 2017 cited by 135

  23. Tumor stem cells fuse with monocytes to form highly invasive tumor-hybrid cells

    Authors: Luis A. Aguirre, Karla Montalbán‐Hernández, José Avendaño‐Ortiz, Elvira Marín, Roberto Lozano‐Rodríguez, Víctor Toledano, Laura Sánchez-Maroto, Verónica Terrón, Jaime Valentín, Elisa Pulido, José Carlos Casalvilla, Carolina Rubio, Luke Diekhorst, Fernando Laso-García, Carlos del Fresno, Ana Collazo-Lorduy, Beatriz Jiménez-Munárriz, Paloma Gómez‐Campelo, Emilio Llanos-González, María Fernández‐Velasco, Carlos Rodríguez‐Antolín, Rebeca Pérez de Diego, Ramón Cantero-Cid, Enrique Hernández-Jiménez, Enrique Álvarez, Rocío Rosas, Blanca D. López‐Ayllón, Javier de Castro, Stefanie K. Wculek, Carolina Cubillos‐Zapata, Inmaculada Ibañez de Cáceres, Prudencio Díaz-Agero, María Gutiérrez Fernández, María P. De Miguel, David Sancho, Leon N. Schulte, Rosario Perona, Cristóbal Belda-Iniesta, Lisardo Boscá, Eduardo López‐Collazo - OncoImmunology 2020 cited by 56

  24. Spatially Preserved Multi-Region Transcriptomic Subtyping and Biomarkers of Chemoimmunotherapy Outcome in Extensive-Stage Small Cell Lung Cancer

    Authors: Melina Peressini, Rosario García-Campelo, Bartomeu Massutí, Cristina Martí, Manuel Cobo, Vanesa Gutiérrez, Manuel Dómine, José Fuentes, Margarita Majem, Javier de Castro, Juan F. Córdoba, María P. Diz, Dolores Isla, Emilio Esteban, Enric Carcereny, Laia Vilà, Alberto Moreno-Vega, Silverio Ros, Amaia Moreno, Francisco J. García, G. Huidobro, Carlos Aguado, Víctor Cebey-López, Javier Valdivia, Ramón Palmero, P. Lianes, Marta López-Brea, Óscar Juan, Mariano Provencio, Edurne Arriola, Javier Baena, Mercedes Herrera, Helena Bote, Magdalena Molero, Vera Adradas, Santiago Ponce-Aix, Ángel Nuñez-Buiza, Álvaro C. Ucero, Susana Hernández, Fernando López‐Ríos, Esther Conde, Luis Paz‐Ares, Jon Zugazagoitia - Clinical Cancer Research 2024 cited by 13